Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR ; volume:13 ; number:7 ; day:12 ; month:7 ; year:2022 ; pages:1-14 ; date:7.2022
Cell death & disease ; 13, Heft 7 (12.7.2022), 1-14, 7.2022
- Creator
-
Lee, Boah
Park, Seung Ju
Lee, Seulgi
Lee, Jinwook
Lee, Eunbeol
Yoo, Eun-Seon
Chung, Won-Suk
Sohn, Jong-Woo
Oh, Byung-Chul
Kim, Seyun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-022-05039-6
- URN
-
urn:nbn:de:101:1-2022092715130799507563
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lee, Boah
- Park, Seung Ju
- Lee, Seulgi
- Lee, Jinwook
- Lee, Eunbeol
- Yoo, Eun-Seon
- Chung, Won-Suk
- Sohn, Jong-Woo
- Oh, Byung-Chul
- Kim, Seyun
- SpringerLink (Online service)
Other Objects (12)
Cholesterol-Lowering Super juice
Cholesterol lowering: role in cancer prevention and treatment
Low-density lipoprotein cholesterol lowering treatment: the current approach
mTOR inhibitors: A novel class of anti-cancer agents
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Cholesterol-stabilized membrane-active nanopores with anticancer activities
Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Cholesterol-Lowering Super juice
Cholesterol lowering: role in cancer prevention and treatment
Low-density lipoprotein cholesterol lowering treatment: the current approach
mTOR inhibitors: A novel class of anti-cancer agents
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Cholesterol-stabilized membrane-active nanopores with anticancer activities
Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Cholesterol-Lowering Super juice
Cholesterol lowering: role in cancer prevention and treatment
Low-density lipoprotein cholesterol lowering treatment: the current approach
mTOR inhibitors: A novel class of anti-cancer agents
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Cholesterol-stabilized membrane-active nanopores with anticancer activities
Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis